News | November 07, 2025
Novo Nordisk’s new CEO doubles down on obesity, diabetes push despite mixed Q3
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
In this role, Neeraj will be responsible for crafting strategy, driving profitable growth through organic and inorganic models, expanding client base
Stephan brings more than 20 years of leadership experience in the pharmaceutical industry
Miels will formally assume the role on January 1, 2026
Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit
His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors
Singhal brings a powerful blend of operational excellence, investor acumen, and visionary thinking
Dr. Rao has over 29 years of experience in manufacturing, R&D, business operations, and customer service
Subscribe To Our Newsletter & Stay Updated
